25-Hydroxyvitamin D concentrations and risk of metabolic syndrome in systemic lupus erythematosus women
Mario García-Carrasco
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, IMSS, Metepec, Puebla, Mexico
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorCorresponding Author
Claudia Mendoza-Pinto
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, IMSS, Metepec, Puebla, Mexico
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Correspondence
Claudia Mendoza-Pinto, Systemic Autoimmune Diseases Research Unit, CIBIOR, Hospital de Especialidades, UMAE, IMSS, Calle 2 Norte 2004, Centro, 72000 Puebla, Puebla, Mexico.
Email: [email protected]
Search for more papers by this authorMiriam Cabrera-Jiménez
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorPamela Munguía-Realpozo
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorSocorro Méndez-Martínez
Research in Health Coordination, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorIvet Etchegaray-Morales
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorRoberto Berra-Romani
Department of Biomedicine, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorIrma Zamora-Ginez
Secretary of Research and Postgraduate Studies, Faculty of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorAurelio López-Colombo
State Research and Education Department, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorMarianne G. Monroy-Azuara
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorAlejandro Ruiz-Arguelles
Laboratorios Clínicos de Puebla, Puebla, Mexico
Search for more papers by this authorMario García-Carrasco
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, IMSS, Metepec, Puebla, Mexico
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorCorresponding Author
Claudia Mendoza-Pinto
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, IMSS, Metepec, Puebla, Mexico
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Correspondence
Claudia Mendoza-Pinto, Systemic Autoimmune Diseases Research Unit, CIBIOR, Hospital de Especialidades, UMAE, IMSS, Calle 2 Norte 2004, Centro, 72000 Puebla, Puebla, Mexico.
Email: [email protected]
Search for more papers by this authorMiriam Cabrera-Jiménez
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorPamela Munguía-Realpozo
Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorSocorro Méndez-Martínez
Research in Health Coordination, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorIvet Etchegaray-Morales
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorRoberto Berra-Romani
Department of Biomedicine, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorIrma Zamora-Ginez
Secretary of Research and Postgraduate Studies, Faculty of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorAurelio López-Colombo
State Research and Education Department, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
Search for more papers by this authorMarianne G. Monroy-Azuara
Department of Immunology and Rheumatology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Search for more papers by this authorAlejandro Ruiz-Arguelles
Laboratorios Clínicos de Puebla, Puebla, Mexico
Search for more papers by this authorAbstract
Objective
A protective function of vitamin D in metabolic syndrome (MetS) has been described. The objective of the present study was to examine the relationship between serum 25-hydroxyvitamin D (25(OH)D) concentrations and MetS in non-diabetic systemic lupus erythematosus (SLE) women.
Methods
Cross-sectional analyses of the relationship between concentrations of 25(OH)D, MetS, and its components were made in 160 non-diabetic SLE women. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III criteria. Serum 25(OH)D was measured by chemiluminescent immunoassay. Serum 25(OH)D concentrations were categorized into quartiles (<16.6, 16.6-21.1, 21.2-26.3, ≥26.4 ng/mL).
Results
A total of 79 (49.3%) SLE women had MetS. Without adjusting for body mass index (BMI) or smoking, the odds of having MetS decreased according to increasing quartiles of 25(OH)D concentrations (P for trend = .03). The odds ratio (OR) of having MetS was 0.4 (95% confidence interval: 0.2-0.9, P = .04) for the highest vs the lowest quartile of 25(OH)D concentrations when adjusted by age. The crude OR of having elevated hypertriglyceridemia decreased according to increasing quartiles of 25(OH)D concentrations (P for trend = .036). However, further adjustments for BMI and smoking removed the inverse association between 25(OH)D concentrations and MetS and its individual components.
Conclusion
In non-diabetic SLE women with mild activity, 25(OH)D concentrations are not associated with MetS and its components.
CONFLICT OF INTEREST
The authors declare that they have no competing interest.
REFERENCES
- 1Lee C, Almagor O, Dunlop DD, et al. Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus. Arthritis Rheum. 2007; 57: 585-592.
- 2Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007; 56: 3412-3419.
- 3Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003; 48: 3159-3167.
- 4Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44: 2331-2337.
10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 5Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56: 1113-1132.
- 6Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35: 2402-2411.
- 7Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008; 28: 629-636.
- 8Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007; 66: 208-214.
- 9Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013; 72: 1308-1314.
- 10Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000; 47: 383-391.
- 11Aranow C, Kamen DL, Dall'Era M, et al. Placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2015; 67: 1848-1857.
- 12Wang L, Zheng Z, Li T, et al. 25-hydroxyvitamin D is associated with metabolic syndrome among premenopausal women with systemic lupus erythematosus in China. Lupus. 2016; 25: 1-7.
- 13Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, et al. Association between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythematosus. Lupus. 2015; 24: 155-163.
- 14Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
- 15Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29: 288-291.
- 16Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39: 363-369.
- 17Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357: 266-281.
- 18Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752.
- 19Huang C-Y, Chang H-H, Lu C-W, Tseng F-Y, Lee L-T, Huang K-C. Vitamin D status and risk of metabolic syndrome among non-diabetic young adults. Clin Nutr. 2015; 34: 484-489.
- 20Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009; 207: 585-590.
- 21Chon SJ, Yun BH, Jung YS, et al. Association between vitamin D status and risk of metabolic syndrome among Korean postmenopausal women. PLoS ONE. 2014; 9:e89721.
- 22George JA, Norris SA, van Deventer HE, Crowther NJ. The association of 25 hydroxyvitamin D and parathyroid hormone with metabolic syndrome in two ethnic groups in South Africa. PLoS ONE. 2013; 8:e61282.
- 23Salman-Monte TC, Torrente-Segarra V, Almirall M, Corzo P, Mojal S, Carbonell-Abelló J. Prevalence and predictors of vitamin D insufficiency in supplemented and non-supplemented women with systemic lupus erythematosus in the Mediterranean region. Rheumatol Int. 2016; 36: 975-985.
- 24Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005; 28: 1228-1230.
- 25Brenner DR, Arora P, Garcia-Bailo B, et al. Plasma vitamin D levels and risk of metabolic syndrome in Canadians. Clin Invest Med. 2011; 34: E377.
- 26Kim S, Lim J, Kye S, Joung H. Association between vitamin D status and metabolic syndrome risk among Korean population: based on the Korean National Health and Nutrition Examination Survey IV-2, 2008. Diabetes Res Clin Pract. 2012; 96: 230-236.
- 27Majumdar V, Nagaraja D, Christopher R. Vitamin D status and metabolic syndrome in Asian Indians. Int J Obes (Lond). 2011; 35: 1131-1134.
- 28Gannage-Yared M-H, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol. 2009; 160: 965-971.
- 29Chiu KC, Chu A, Go V, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004; 79: 820-825.
- 30Lu L, Yu Z, Pan A, et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care. 2009; 32: 1278-1283.
- 31Kim MK, Il Kang M, Won O, et al. The association of serum vitamin D level with presence of metabolic syndrome and hypertension in middle-aged Korean subjects. Clin Endocrinol (Oxf). 2010; 73: 330-338.
- 32Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011; 94: 486-494.
- 33Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab. 2006; 290: E916-E924.
- 34Rosenblum JL, Castro VM, Moore CE, Kaplan LM. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr. 2012; 95: 101-108.
- 35Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. Eur J Endocrinol. 2008; 159: 675-684.
- 36Ajabshir S, Asif A, Nayer A. The effects of vitamin D on the renin-angiotensin system. J Nephropathol. 2014; 3: 41-43.
- 37Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism. 2000; 49: 1501-1505.
- 38Miloslavsky EM, Naden RP, Bijlsma J, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017; 76: 543-546.
Citing Literature
